1. Home
  2. AVXL vs YDES Comparison

AVXL vs YDES Comparison

Compare AVXL & YDES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AVXL
  • YDES
  • Stock Information
  • Founded
  • AVXL 2004
  • YDES 2013
  • Country
  • AVXL United States
  • YDES Taiwan
  • Employees
  • AVXL N/A
  • YDES N/A
  • Industry
  • AVXL Biotechnology: Biological Products (No Diagnostic Substances)
  • YDES
  • Sector
  • AVXL Health Care
  • YDES
  • Exchange
  • AVXL Nasdaq
  • YDES Nasdaq
  • Market Cap
  • AVXL 956.7M
  • YDES 1.1B
  • IPO Year
  • AVXL N/A
  • YDES N/A
  • Fundamental
  • Price
  • AVXL $9.80
  • YDES $18.00
  • Analyst Decision
  • AVXL Strong Buy
  • YDES
  • Analyst Count
  • AVXL 2
  • YDES 0
  • Target Price
  • AVXL $44.00
  • YDES N/A
  • AVG Volume (30 Days)
  • AVXL 1.2M
  • YDES 103.6K
  • Earning Date
  • AVXL 08-12-2025
  • YDES 09-30-2025
  • Dividend Yield
  • AVXL N/A
  • YDES N/A
  • EPS Growth
  • AVXL N/A
  • YDES N/A
  • EPS
  • AVXL N/A
  • YDES N/A
  • Revenue
  • AVXL N/A
  • YDES $510,360.00
  • Revenue This Year
  • AVXL N/A
  • YDES N/A
  • Revenue Next Year
  • AVXL N/A
  • YDES N/A
  • P/E Ratio
  • AVXL N/A
  • YDES N/A
  • Revenue Growth
  • AVXL N/A
  • YDES 45.76
  • 52 Week Low
  • AVXL $5.03
  • YDES $5.30
  • 52 Week High
  • AVXL $14.44
  • YDES $25.00
  • Technical
  • Relative Strength Index (RSI)
  • AVXL 58.71
  • YDES N/A
  • Support Level
  • AVXL $8.80
  • YDES N/A
  • Resistance Level
  • AVXL $10.04
  • YDES N/A
  • Average True Range (ATR)
  • AVXL 0.49
  • YDES 0.00
  • MACD
  • AVXL 0.18
  • YDES 0.00
  • Stochastic Oscillator
  • AVXL 73.79
  • YDES 0.00

About AVXL Anavex Life Sciences Corp.

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.

About YDES YD Bio Limited Ordinary Shares

YD Bio Ltd is a biopharmaceutical company focusing on blood-based cancer detection, the development of stem cell- and exosome-based therapeutics with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need and serving as a trusted supplier of clinical testing drugs for pharmaceutical companies. Stem cell therapy uses versatile cells to repair or regenerate damaged tissues, offering innovative treatments for injuries, degenerative diseases, and immune disorders with potential for personalized medicine and tissue engineering.

Share on Social Networks: